Stock Events

Stock Events

Inventiva 

$4.76
95
+$0.12+2.59% Wednesday 20:00
+$0.00+0%Wednesday 20:00After hours

Statistics

Day High
4.79
Day Low
4.7
52W High
7.98
52W Low
3.35
Volume
23,405
Avg. Volume
-
Mkt Cap
1.12B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25SepExpected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-2.07
-1.38
-0.69
0
Expected EPS
-0.41799396
Actual EPS
N/A

Financials

-7,881.61%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5.28MRevenue
-416.46MNet Income

Analyst Ratings

13.00Average Price Target
The highest estimate is 13.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVA. It's not an investment recommendation.
NVIDIA
10
NVDA
TotalEnergies
9
TTE.PA
Nanobiotix
8
NANO.PA
Microsoft
7
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.73B
Madrigal Pharmaceuticals is involved in developing solutions for nonalcoholic steatohepatitis (NASH), a key area of focus for Inventiva.
Viking Therapeutics
VKTX
Mkt Cap3.87B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a competitor.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, competing with Inventiva's pipeline.
Agenus
AGEN
Mkt Cap329.47M
Agenus Inc. is focused on immuno-oncology but its interest in novel therapeutic approaches can indirectly compete with Inventiva's innovative treatments.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a diverse biopharmaceutical portfolio that includes research in fibrosis, making it a competitor.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad research portfolio that includes fibrosis and other areas relevant to Inventiva's interests.
Novartis
NVS
Mkt Cap286.78B
Novartis AG conducts extensive research in areas including fibrosis and metabolic diseases, overlapping with Inventiva's therapeutic areas.

About

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Show more...
CEO
Andrew Obenshain
Employees
77
Country
France
ISIN
US46124U1079
WKN
000A2P796

Listings

XETRA
DE
6IV.XETRA
STU
DE
6IV.STU
STU
DE
6IVA.STU
MU
DE
6IV.MU

0 Comments

Share your thoughts

FAQ

What is Inventiva stock price today?▼
The current price of IVA is $4.76 USD — it has increased by +2.59% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.
What is Inventiva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Inventiva stocks are traded under the ticker IVA.
Is Inventiva stock price growing?▼
IVA stock has risen by +3.48% compared to the previous week, the month change is a +7.81% rise, over the last year Inventiva has showed a +3.93% increase.
What is Inventiva market cap?▼
Today Inventiva has the market capitalization of 1.12B
When is the next Inventiva earnings date?▼
Inventiva is going to release the next earnings report on September 25, 2026.
What were Inventiva earnings last quarter?▼
IVA earnings for the last quarter are -1.08 USD per share, whereas the estimation was -0.55 USD resulting in a -97.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inventiva revenue for the last year?▼
Inventiva revenue for the last year amounts to 5.28M USD.
What is Inventiva net income for the last year?▼
IVA net income for the last year is -416.46M USD.
How many employees does Inventiva have?▼
As of August 20, 2026, the company has 77 employees.
In which sector is Inventiva located?▼
Inventiva operates in the Health & Wellness sector.
When did Inventiva complete a stock split?▼
Inventiva has not had any recent stock splits.
Where is Inventiva headquartered?▼
Inventiva is headquartered in Daix, France.